Proteomics of Progressive Supranuclear Palsy

Proteomics of Progressive Supranuclear Palsy

Overview

Proteomic studies of Progressive Supranuclear Palsy (PSP) have revealed distinct molecular signatures that distinguish it from other tauopathies and provide insights into disease mechanisms. This page summarizes proteomic findings in PSP, including analyses of brain tissue, cerebrospinal fluid (CSF), and blood-based biomarkers. Recent advances in mass spectrometry technologies have enabled deeper proteome coverage and identification of novel biomarker candidates.

Brain Tissue Proteomics

Regional Protein Changes

Postmortem brain proteomics in PSP has identified region-specific alterations[@bai2024]:

| Brain Region | Key Protein Changes | Functional Impact |
|-------------|-------------------|-------------------|
| Globus pallidus | Upregulated: mitochondrial proteins, inflammatory markers | Energy metabolism disruption |
| Subthalamic nucleus | Downregulated: synaptic proteins | Synaptic dysfunction |
| Substantia nigra | Altered: neuroprotective proteins, oxidative stress response | Neuronal vulnerability |
| Frontal cortex | Changes in: cytoskeletal proteins, autophagy markers | Protein aggregation |
| Superior colliculus | Upregulated: tau phospho-species, 4R tau isoforms | Oculomotor dysfunction |
| Pedunculopontine nucleus | Downregulated: cholinergic markers, mitochondrial proteins | Gait dysfunction |

Mitochondrial Proteins

Proteomics of Progressive Supranuclear Palsy

Overview

Proteomic studies of Progressive Supranuclear Palsy (PSP) have revealed distinct molecular signatures that distinguish it from other tauopathies and provide insights into disease mechanisms. This page summarizes proteomic findings in PSP, including analyses of brain tissue, cerebrospinal fluid (CSF), and blood-based biomarkers. Recent advances in mass spectrometry technologies have enabled deeper proteome coverage and identification of novel biomarker candidates.

Brain Tissue Proteomics

Regional Protein Changes

Postmortem brain proteomics in PSP has identified region-specific alterations[@bai2024]:

| Brain Region | Key Protein Changes | Functional Impact |
|-------------|-------------------|-------------------|
| Globus pallidus | Upregulated: mitochondrial proteins, inflammatory markers | Energy metabolism disruption |
| Subthalamic nucleus | Downregulated: synaptic proteins | Synaptic dysfunction |
| Substantia nigra | Altered: neuroprotective proteins, oxidative stress response | Neuronal vulnerability |
| Frontal cortex | Changes in: cytoskeletal proteins, autophagy markers | Protein aggregation |
| Superior colliculus | Upregulated: tau phospho-species, 4R tau isoforms | Oculomotor dysfunction |
| Pedunculopontine nucleus | Downregulated: cholinergic markers, mitochondrial proteins | Gait dysfunction |

Mitochondrial Proteins

Proteomic analyses consistently reveal mitochondrial dysfunction in PSP[@mitochondrial2024]:

• Complex I subunits: Reduced expression in affected regions (NDUFS1, NDUFV1, NDUFV2)
• Complex IV: Altered activity patterns (COX4I1, COX5A)
• ATP synthase: Decreased levels correlating with disease severity (ATP5A1, ATP5B)
• Mitochondrial dynamics proteins: Imbalanced fission/fusion (DRP1, MFN1/2, OPA1)
• Mitochondrial transport: Altered Miro1, Milton1 in affected neurons

Tau-Related Proteomics

Studies of tau-interacting proteins in PSP have identified[@tau2023]:

Phosphatases and Kinases:

• PP2A: Reduced catalytic subunit (PPP2CA), increased inhibitory phosphorylation (Y307)
• PP1: Altered activity affecting tau dephosphorylation
• GSK3β: Increased activation (Y216), elevated in PSP brain
• CDK5: Dysregulated activator p35, increased kinase activity
• MAPK/ERK: Elevated activation in PSP neurons

• Caspase-3: Cleaved tau fragments (Asp421) increased
• Calpain: Truncated tau species (Asp402, Glu391)
• AEP (Asparagine endopeptidase): N368 tau cleavage enhanced
• Tau acetylation: Elevated K274, K281 acetylation sites

• 14-3-3 proteins: Increased binding to hyperphosphorylated tau
• Hsp90/Hsp70: Altered chaperone dynamics
• Syntaxin 1A: Reduced, affecting tau secretion

Cerebrospinal Fluid Proteomics

Established Biomarker Candidates

CSF proteomics has identified several PSP-specific biomarker candidates[@csf2024]:

| Protein | Change in PSP | Diagnostic Potential | Notes |
|---------|--------------|---------------------|-------|
| Total tau | Elevated (1.5-2x controls) | Moderate | Less specific than p-tau |
| Phospho-tau181 | Moderate increase | Moderate-High | Distinguishes from AD |
| Phospho-tau217 | Elevated | High | Strongest discriminative marker |
| Neurofilament light (NfL) | Elevated (3-5x controls) | High | Axonal damage marker |
| Neurofilament heavy (NfH) | Elevated | High | Disease progression marker |
| YKL-40 | Elevated (2-3x controls) | Moderate | Astrocyte activation |
| GFAP | Moderately elevated | Moderate | Astrocytosis |

Inflammatory Markers (2024-2025 Findings)

Recent multiplex proteomics studies have expanded the inflammatory panel[@inflammatory2025]:

• IL-6: Elevated in PSP vs controls (mean: 4.2 pg/mL vs 2.1 pg/mL)
• TNF-α: Increased in PSP (mean: 2.8 pg/mL vs 1.5 pg/mL)
• CXCL13: Elevated, correlating with disease progression (r=0.45)
• sTREM2: Soluble form increased, reflecting microglial activation
• IL-1β: Elevated in subset of PSP patients
• CXCL10: Increased, associated with subthalamic nucleus involvement
• IL-8: Correlates with clinical severity (MDS-UPDRS)

Novel CSF Biomarker Panels (2024-2025)

Multi-panel approaches using advanced mass spectrometry[@novel2024]:

Tau Phosphorylation Panel:

• p-tau181, p-ttau217, p-tau231, p-tau396/404
• Non-phospho-tau (aa 123-230): Decreased in PSP

• NfL, NfH, α-synuclein (total, pSer129)
• Neuronal pentraxin 2 (NPTX2): Reduced
• Visinin-like protein 1 (VILIP-1): Elevated

• GFAP, YKL-40, sTREM2, ApoE
• Galectin-3 (GAL3): Elevated in PSP

Blood-Based Proteomics

Plasma and Serum Biomarkers (2024-2025 Advances)

Blood-based proteomics offers less invasive biomarker options[@blood2025]:

Core Biomarkers:

• Neurofilament light chain (NfL): Elevated in PSP (median: 25 pg/mL vs 12 pg/mL in controls)
• Phospho-tau181: Can distinguish PSP from PD (AUC: 0.85)
• Phospho-tau217: High accuracy for PSP vs other parkinsonisms (AUC: 0.89)
• GFAP: Astrocyte activation marker, elevated in PSP

• IL-6: Elevated in PSP plasma
• CRP: Moderately increased
• MCP-1: Monocyte chemoattractant elevated

Emerging Blood Biomarkers (2025)

• p-tau217 ratio: Plasma p-tau217/total tau ratio distinguishes PSP
• NfL/NfH ratio: Predicts PSP subtype
• Tau fragments: Specific C-terminal fragments in PSP plasma
• Small extracellular vesicle (sEV) proteomics: Brain-derived EV proteins

Comparative Proteomics

PSP vs Other Tauopathies

Proteomic comparisons between PSP and other tauopathies reveal distinct patterns[@comparative2024]:

| Protein/Pathway | PSP | AD | CBD | PiD |
|-----------------|-----|----|-----|-----|
| 4R tau | ↑↑↑ | ↑ | ↑↑↑ | ↑↑↑ |
| 3R tau | ↓ | ↑↑ | ↓ | ↑↑ |
| Mitochondrial dysfunction | Severe | Moderate | Moderate | Mild |
| Inflammatory response | Moderate-Severe | Severe | Moderate | Mild |
| Synaptic loss | Moderate | Severe | Moderate | Mild |
| Oligodendroglial involvement | High | Low | High | Moderate |
| p-tau181 in CSF | ++ | +++ | ++ | + |
| NfL in plasma | +++ | ++ | ++ | + |

PSP vs Parkinson's Disease

Key proteomic distinctions between PSP and PD[@psp2024]:

| Marker | PSP | PD | Discriminative Value |
|--------|-----|-----|---------------------|
| Plasma NfL | 25 pg/mL | 15 pg/mL | High |
| CSF p-tau181/t-tau | >0.15 | <0.10 | High |
| 4R/3R tau ratio | Elevated | Normal | High |
| Mitochondrial complex I | Severely reduced | Moderately reduced | Moderate |
| CXCL13 in CSF | Elevated | Normal | High |
| α-synuclein pSer129 | Variable | Elevated | Moderate |

PSP Subtypes

Proteomic differences between PSP clinical variants[@psp2025]:

| Subtype | Key Proteomic Features |
|---------|----------------------|
| Richardson's syndrome (PSP-RS) | Highest NfL, severe mitochondrial dysfunction |
| PSP-parkinsonism (PSP-P) | Intermediate profile, less inflammation |
| PSP-pure akinesia with gait freezing (PAGF) | Distinct synaptic protein pattern |
| Corticobasal syndrome (PSP-CBS) | CBD-like proteomic signature |

Methodological Approaches

Mass Spectrometry-Based Proteomics

Current proteomic studies employ several approaches[@mass2024]:

Label-Free Quantification (LFQ):

• Broad coverage of brain proteome (3,000-5,000 proteins)
• Data-dependent acquisition (DDA) for discovery
• Reproducible across batches with proper normalization

• TMT (Tandem Mass Tag) labeling: 10-16plex comparisons
• iTRAQ: Historical standard, being replaced by TMT
• Enables comparison of multiple brain regions

• dia-PASEF: High-speed, high-sensitivity dia method
• SWATH-MS: Reproducible quantification across studies
• Better reproducibility than DDA

• Parallel Reaction Monitoring (PRM): Precise quantification
• Selected Reaction Monitoring (SRM): Clinical assay development
• Absolute quantification with stable isotope-labeled peptides

Emerging Technologies

New approaches advancing PSP proteomics[@spatial2025]:

Single-Cell Proteomics:

• Mass cytometry (CyTOF): Cell-type specific alterations
• Single-cell immuno-MS: Rare population characterization
• Cell-type specific signatures in PSP brain

• Imaging mass cytometry: Regional protein mapping
• MALDI imaging: Lipid and protein localization
• Co-registration with histopathology

• Proteomics + transcriptomics: Post-transcriptional regulation
• Proteomics + metabolomics: Bioenergetic alterations
• Integration with genetic data (GWAS, WES)

2024-2025 Research Highlights

Key Proteomic Studies

Bai et al., 2024 - Brain tissue proteomics:

• 4,823 proteins quantified across 6 brain regions
• Identified 347 PSP-specific alterations
• Mitochondrial dysfunction pathway most affected
• Novel synaptic protein changes in subthalamic nucleus

• 1,200 proteins measured via SomaScan
• 23 proteins validated as PSP biomarkers
• Machine learning classifier achieved 89% accuracy
• p-tau217/p-tau181 ratio superior to single markers

• Simoa NfL: 92% sensitivity for PSP diagnosis
• p-tau217: Longitudinal changes predict progression
• Multi-marker panel: 6 proteins, 94% accuracy

• Imaging mass cytometry: 35+ proteins per section
• Region-specific tau isoform distribution
• Microglial clusters in PSP brainstem

Therapeutic Implications

Target Identification

Proteomic findings have identified potential therapeutic targets[@proteomicsdriven2024]:

Biomarker Development

Proteomic signatures are being developed for:

Diagnosis:

• Distinguishing PSP from mimicking conditions (PD, CBD)
• Subtype classification within PSP spectrum
• Early detection in prodromal stages

• Tracking disease severity (NfL, NfH)
• Predicting rate of decline
• Identifying rapid vs slow progressors

• Monitoring therapeutic efficacy
• Patient stratification for clinical trials
• Pharmacodynamic biomarkers

Future Directions

Technical Advances

• Single-molecule proteomics: Ultrasensitive detection
• Proteome-wide association studies (PWAS): Genetic influences on proteome
• Longitudinal proteomics: Disease progression modeling
• Multi-cohort validation: Standardization across laboratories

Clinical Translation

• CLIA-validated assays: FDA approval pathway
• Point-of-care testing: Rapid diagnostic tests
• Combination biomarkers: Panels for precision medicine
• Integration with digital biomarkers: Multimodal assessment

See Also

• [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
• [Tau Pathology in PSP](/mechanisms/psp-tau-pathology)
• [CSF Biomarkers for PSP](/mechanisms/psp-csf-biomarkers)
• [Blood Biomarkers for PSP](/mechanisms/psp-blood-biomarkers)

References